We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple all... Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies. Show more
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Cemacabtagene Ansegedleucel (Cema-Cel) Expanded CD19 Oncology Rights to Include all EU Member States and the United Kingdom, Reinforcing Company’s Conviction in the Unique Opportunity in Large B...
Conference Call and Webcast Scheduled for May 13, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a...
$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)ALLO-316 Illustrates Proof-of-Concept in...
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.03 | -1.18577075099 | 2.53 | 2.66 | 2.31 | 2847973 | 2.41744478 | CS |
4 | -0.58 | -18.8311688312 | 3.08 | 3.65 | 2.31 | 2691768 | 2.73376784 | CS |
12 | -3.15 | -55.7522123894 | 5.65 | 5.775 | 2.31 | 2423981 | 3.55685891 | CS |
26 | 0.15 | 6.3829787234 | 2.35 | 5.775 | 2.23 | 2730332 | 3.49201265 | CS |
52 | -2.7 | -51.9230769231 | 5.2 | 6.05 | 2.23 | 2458714 | 3.7976259 | CS |
156 | -23.13 | -90.2458056964 | 25.63 | 27.86 | 2.23 | 1983183 | 8.31474028 | CS |
260 | -24.04 | -90.580256217 | 26.54 | 55 | 2.23 | 1490539 | 13.24596995 | CS |
Symbol | Price | Vol. |
---|---|---|
NVOSNovo Integrated Sciences Inc | $ 1.2999 (188.23%) | 268.33M |
GWAVGreenwave Technology Solutions Inc | $ 0.0398 (-5.24%) | 224.71M |
FFIEFaraday Future Intelligent Electric Inc | $ 0.5472 (-3.20%) | 179.44M |
CRKNCrown Electrokinetics Corporation | $ 0.1082 (-4.67%) | 116.64M |
SQQQProShares UltraPro Short QQQ | $ 10.42 (3.99%) | 112.97M |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions